Hybio Pharmaceutical (300199) — Tangible Net Worth Ratio
Hybio Pharmaceutical (300199) has a Tangible Net Worth Ratio of 36.6% as of September 2025. This metric is calculated by deducting intangible assets (CN¥422.37 Million) from net assets (CN¥666.08 Million) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. See 300199 net asset value for net asset value and shareholders' equity analysis.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Hybio Pharmaceutical Tangible Net Worth Ratio (2007–2024)
This chart shows how Hybio Pharmaceutical's Tangible Net Worth Ratio has changed across 18 annual periods from 2007 to 2024. As of September 2025, the ratio stands at 36.6%, reflecting net assets of CN¥666.08 Million with intangible assets of CN¥422.37 Million CNY. Also explore Hybio Pharmaceutical equity growth rate to track the company's year-over-year net asset growth rate.
Annual Tangible Net Worth Ratio for Hybio Pharmaceutical (2007–2024)
The table below presents the year-by-year Tangible Net Worth Ratio for Hybio Pharmaceutical from 2007 to 2024, covering 18 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For the full company profile including market capitalisation, see 300199 company net worth.
| Year | Tangible NW Ratio | Net Assets (CNY) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 28.0% | CN¥597.05 Million | CN¥430.09 Million | CN¥3.01 Billion | ▼ -17.2 pp |
| 2023 | 45.2% | CN¥783.21 Million | CN¥429.59 Million | CN¥3.28 Billion | ▼ -15.7 pp |
| 2022 | 60.9% | CN¥1.30 Billion | CN¥507.30 Million | CN¥3.61 Billion | ▼ -10.0 pp |
| 2021 | 70.9% | CN¥1.65 Billion | CN¥479.20 Million | CN¥3.91 Billion | ▲ +3.8 pp |
| 2020 | 67.2% | CN¥1.68 Billion | CN¥550.89 Million | CN¥4.02 Billion | ▼ -8.1 pp |
| 2019 | 75.2% | CN¥2.23 Billion | CN¥552.89 Million | CN¥4.72 Billion | ▼ -9.4 pp |
| 2018 | 84.6% | CN¥3.39 Billion | CN¥521.03 Million | CN¥5.66 Billion | ▼ -3.7 pp |
| 2017 | 88.3% | CN¥3.88 Billion | CN¥453.90 Million | CN¥5.30 Billion | ▲ +1.4 pp |
| 2016 | 86.9% | CN¥3.60 Billion | CN¥471.82 Million | CN¥4.46 Billion | ▲ +4.6 pp |
| 2015 | 82.3% | CN¥2.64 Billion | CN¥467.05 Million | CN¥3.55 Billion | ▼ -12.9 pp |
| 2014 | 95.2% | CN¥1.30 Billion | CN¥62.70 Million | CN¥1.70 Billion | ▲ +0.2 pp |
| 2013 | 95.0% | CN¥1.12 Billion | CN¥56.28 Million | CN¥1.29 Billion | ▼ -3.6 pp |
| 2012 | 98.6% | CN¥1.02 Billion | CN¥14.23 Million | CN¥1.12 Billion | ▲ +0.2 pp |
| 2011 | 98.4% | CN¥976.09 Million | CN¥15.48 Million | CN¥1.04 Billion | ▲ +5.4 pp |
| 2010 | 93.0% | CN¥180.59 Million | CN¥12.58 Million | CN¥212.89 Million | ▲ +3.1 pp |
| 2009 | 89.9% | CN¥127.74 Million | CN¥12.84 Million | CN¥182.47 Million | ▲ +2.8 pp |
| 2008 | 87.2% | CN¥99.23 Million | CN¥12.72 Million | CN¥136.55 Million | ▼ -12.8 pp |
| 2007 | 100.0% | CN¥48.70 Million | CN¥0.00 | CN¥58.24 Million | — |